• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Transl Med . Enhanced SARS-CoV-2 neutralization by dimeric IgA

tetano

Editor, Senior Moderator
Sci Transl Med


. 2020 Dec 7;eabf1555.
doi: 10.1126/scitranslmed.abf1555. Online ahead of print.
Enhanced SARS-CoV-2 neutralization by dimeric IgA


Zijun Wang[SUP] 1 [/SUP], Julio C C Lorenzi[SUP] 1 [/SUP], Frauke Muecksch[SUP] 2 [/SUP], Shlomo Finkin[SUP] 1 [/SUP], Charlotte Viant[SUP] 1 [/SUP], Christian Gaebler[SUP] 1 [/SUP], Melissa Cipolla[SUP] 1 [/SUP], Hans-Heinrich Hoffmann[SUP] 3 [/SUP], Thiago Y Oliveira[SUP] 1 [/SUP], Deena A Oren[SUP] 4 [/SUP], Victor Ramos[SUP] 1 [/SUP], Lilian Nogueira[SUP] 1 [/SUP], Eleftherios Michailidis[SUP] 3 [/SUP], Davide F Robbiani[SUP] 5 [/SUP], Anna Gazumyan[SUP] 1 [/SUP], Charles M Rice[SUP] 3 [/SUP], Theodora Hatziioannou[SUP] 2 [/SUP], Paul D Bieniasz[SUP] 2 6 [/SUP], Marina Caskey[SUP] 1 [/SUP], Michel C Nussenzweig[SUP] 7 6 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), primarily infects cells at mucosal surfaces. Serum neutralizing antibody responses are variable and generally low in individuals that suffer mild forms of COVID-19. Although potent IgG antibodies can neutralize the virus, less is known about secretory antibodies such as IgA that might impact the initial viral spread and transmissibility from the mucosa. Here we characterize the IgA response to SARS-CoV-2 in a cohort of 149 convalescent individuals following diagnosis with COVID-19. IgA responses in plasma generally correlated with IgG responses. Further, clones of IgM-, IgG-, and IgA-producing B cells were derived from common progenitor cells. Plasma IgA monomers specific to SARS-CoV-2 proteins were demonstrated to be two-fold less potent than IgG equivalents. However, IgA dimers, the primary form of antibody in the nasopharynx, were on average fifteen times more potent than IgA monomers against the same target. Thus, dimeric IgA responses may be particularly valuable for protection against SARS-CoV-2 and for vaccine efficacy.
 
Back
Top Bottom